Pulmonary hypertension in interstitial lung disease

Pulmonary Arterial Hypertension and Interstitial Lung Diseases: A Clinical Guide

Volumn , Issue , 2009, Pages 13-50

  Carbone, Roberto G ^a   Monselise, Assaf ^b   Bottino, Giovanni ^a  

^a Regional Hospital   (Italy)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78649426240     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-60327-074-8_2     Document Type: Chapter

References (103)

1. Humbert M, Deng Z, Simmoneau G, et al. BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivates. Eur Respir J 2002;20:518-523.
2. Morse J, Barst R, Horn E, et al. Pulmonary hypertension in scleroderma spectrum of disease lack of bone morphogenetic protein receptor-2 mutations. J Rheumatol 2002;29:2379-2381.
3. Tew MB, Arnett PC, Reveille JD, et al. Mutation of bone morphogenetic protein receptor type 2 are not found in patients with pulmonary hypertension and underlying connective tissue diseases. Arthritis Rheum 2002;46:2829-2830.
4. Trembart J R C, Thomson JR, Machado RD, et al. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasis. N Engl J Med 2001;345:325-334.
5. Du I, Sullivan CC, Chu D, et al. Signaling molecules in non familial pulmonary hypertension. N Eng J Med 2003;92:984-991.
6. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Eng J Med 2004;351:1655-1665.
7. Nogee LM, Dunbar III, AE, Wert SE, et al. A mutation in the surfactant protein C gene associated with familial interstitial lung disease. N Eng J Med 2001;344;573-579.
8. Amin RS, Wert SE, Baughman RP, et al. Surfactant protein deficiency in familial interstitial lung disease. J Pediatr 2001;139:85-92.
9. Khalil N, Parekh T V, O'Connor R, et al. Regulation of the effect of TGF-beta 1 by activation of latent of TGF-beta 1 and differential expression of TGF-beta receptors/T-beta R-1 and T beta R-2) in idiopathic pulmonary fibrosis. Thorax 2001;56:907-915.
10. Sime PJ, Xing Z, Graham FL. Adenovector-mediated gene transfer of active transforming grown factor-beta 1 induces prolonged severe fibrosis in rat lung. J Clin Invest 1997;100:768-777.
11. Whyte M, Hubbard R, Meliconi R, et al. Increased risk of fibrosing alveolitis associated with interleukin-1 receptor antagonist and tumor necrosis factor-a gene polymorphisms. Am J Respir Crit Care Med 2000;162:755-758.
12. Zorzetto M, Ferrarotti I, Trisolini R, et al. Complement receptor 1 gene polymorphisms are associated with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003;168:330-334.
13. Pantelidis P, Fanning GC, Wells AU, et al. Analysis of tumor necrosis factor-α, lymphotoxin-α, tumor necrosis factor receptor II, and interleukin-6 polymorphisms in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2001;163:1432-1436.
14. Xaubert A, Marin-Arguedas A, Lario S, et al. Transforming growth factor-β1 gene polymorphisms are associated with disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003;168:431-435.
15. Reeve HL, Archer SL, Weir EK. Ion channels in the pulmonary vasculature. Pulm Pharmacol Ther 1997;10:243-252.
16. Weir EK, Reeve HL, Talorova S, et al. Oxygen sensing in the pulmonary vasculature. In: Lopez-Barneo J, Weir EK, editors. Oxygen regulation of ion channels and gene expression. Armonk, NY: Futura Publishing Company, Inc.; 1998. p. 193-206.
17. + channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation 1998;14:1400-1406.
18. Marshall RB, Mamary C A J, Verhoeven AJ, et al. Pulmonary artery NADPH-oxidase is activated in hypoxic pulmonary vasoconstriction. Am J Respir Cell Mol Biol 1996;15:633-644.
19. Weissmann N, Tadic A, Winterhalder S, et al. Inhibition of hypoxic pulmonary vasoconstriction by superoxide dismutase inhibitors in isolated rabbit lungs. Am J Respir Crit Care Med 1999;159:A 569.
20. Robertson TP, Hague D, Aaronson PI, et al. Voltage-independent calcium entry in hypoxic pulmonary vasoconstriction of intrapulmonary arteries of the rat. J Physiol 2000;525:669-680.
21. ++ conductances in pulmonary artery cells. Am J Physiol 1994:267:L52-L63.
22. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-415.
23. Giaid A, Yanagisawa M, Langleben SD, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Eng J Med 1993;328:1732-1739.
24. Arai S, Hori S, Aramori I, et al. Cloning and expression of a cDNA encoding an endothelin receptor. Nature (Lond) 1990;348:730-732.
25. Sakurai T, Yanagisawa M, Takuwa Y, et al. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature (Lond) 1990;348:732-735.
26. Giaid A, Michel RP, Stewart DJ, et al. Expression of endothelin-1 in patients with cryptogenic fibrosing alveolitis. Lancet 1993;341:1550-1554.
27. Ugucccioni M, Pulsatelli L, Grigolo B et al. Endothelin-1 in idiopathic pulmonary fibrosis. J Clin Pathol 1995;48:330-334.
28. Abraham DJ, Vancheenswaran R, Dashwood MR, et al. Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am J Pathol 1997;151:831-841.
29. Park SH, Saleh D, Giaid A, et al. Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist. Am J Respir Crit Care Med 1997;156:831-841.
30. Hocher B, Schwartz A, Fagan KA, et al. Pulmonary fibrosis and chronic lung inflammation in ET-1 transgenic mice. Am J Respir Cell Mol Biol 2000;23:19-26.
31. Turner-Warwick M. Precapillary systemic-pulmonary anastomoses. Thorax 1963;18:225-237.
32. Peao M N D, Aguas AP, De Sa CM, et al. Neoformation of blood vessels in association with a rat lung fibrosis induced by bleomycin. Anat Rec 1994;238:57-67.
33. Keane MP, Arenberg DA, Lynch JP 3rd, et al. The CXC chemokines, IL-8 and IP-10regulate angiogenic activity in idiopathic pulmonary fibrosis. J Immunol 1997;159:1437-1453.
34. Keane MP, Belperio JA, Burdick M, et al. ENA-78 is an important angiogenic factor in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2001;164:2239-2242.
35. Hyde DM, Henderson TS, Giri SN, et al. Effect of murine gamma interferon on the cellular responses to bleomycin in mice. Exp Lung Res 1988;14:687-704.
36. Keane MP, Belperio JA, Arenberg DA, et al. IFN-gamma-inducible protein-10 attenuates bleomycin-induced pulmonary fibrosis via inhibition of angiogenesis. J Immunol 1999;163:5686-5692.
37. Rich S, editor. Primary pulmonary hypertension. Executive summary from the World Symposium: Primary Pulmonary Hypertension 1998. htpp://www.who.int/ ncd/cvd/pph.html. Accessed 14 Aug. 2008.
38. Morell NW, Morris KG, Stenmark KR. Role of angiotensin-converting enzyme activity and expression is increased during hypoxic pulmonary hypertension. Cardiovasc Res 1997;34:393-403.
39. Davis P, Burke G, Reid I. The structure of the wall of the rat interacinar pulmonary artery: an electron microscopic study of microdissected preparations. Microvasc Res 1986;32:50-63.
40. Jones RC. Role of interstitial fibroblasts and intermediate cells in microvascular remodelling in pulmonary hypertension. Eur Respir Rev 1993;3:569-575.
41. Tuder RM, Groves B, Badesch DB, et al. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 1994;144:275-285.
42. Yi ES, Kim H, Ahn H, et al. Distribution of obstructive intimal lesions and their cellular phenotypes in chronic pulmonary hypertension. A morphometric and immunohistochemical study. Am J Respir Crit Care Med 2000;162:1577-1586.
43. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Eng J Med 1993;328:1732-1739.
44. Wang R, Ibarra-Sunga O, Verlinski L, et al. Abrogation of bleomycin-induced epithelial apoptosis and lung fibrosis by captopril or by a caspase inhibitor. Am J Physiol Lung Cell Mol Physiol 2000;279:L143-L151.
45. Kuwano K, Kunitake R, Maeyama T, et al. Attenuation of bleomycin-induced pneumopathy in mice by a caspase inhibitor. Am J Physiol Lung Cell Mol Physiol 2001;280:L316-L325.
46. Hagimoto N, Kuwano K, Inoshima M, et al. TGF-beta 1 as an enhancer of Fas-mediated apoptosis of lung epithelial cells. J Immunol 2002;168:6470-6478.
47. Wang R, Alam G, Zagariya A, et al. Apoptosis of lung epithelial cells in response to TNF-alpha requires angiotensin II generation de novo. J Cell Physiol 2000;185:253-259.
48. Keane MP, Arenberg DA, Lynch JP 3rd, et al. The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. J Immunol 1997;159:1437-1443.
49. Renzoni EA, Walsh DA, Salmon M, et al. Interstitial vascularity in fibrosing alveolitis. Am J Respir Crit Care Med 2003;167:438-443.
50. Koyama S, Sato E, Haniuda H, et al. Decreased level of vascular endothelial grown factor. Am Respir J Crit Care Med 2002;166:382-385.
51. Weller PA. Eosinophils and fibroblasts: the medium in the mesenchyme. Am J Respir Cell Mol Biol 1989:1:267-268.
52. Elias JA, Freundlich B, Kern JA, Rosenbloom J. Cytokine networks in the regulation of inflammation and fibrosis in the lung. Chest 1990;97:1439-1445.
53. Gurujeyalakshmi G, Giri SN. Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin-mouse model of lung fibrosis: down regulation of TGF-β and procollagen I and III gene expression. Exp Lung Res 1995;21:791-808.
54. Prior C, Haslam PL. In vivo levels and in vitro production of interferon-gamma in fibrosing interstitial lung diseases. Clin Exp Immunol 1992;88:280-287.
55. Gaensler EA, Carrington CB. Open biopsy for chronic diffuse infiltrative lung disease: clinical, roentgenographic, and physiologic correlation in 502 patients. Ann Thorac Surg 1980;30:411-426.
56. Padley S P G, Hansell DM, Flower C D R, et al. Comparative accuracy of high resolution computed tomography and chest radiography in the diagnosis of chronic diffuse infiltrative lung disease. Clin Radiol 1991;44:222-226.
57. Lee KS, Primack SL, Staples CA, et al. Chronic infiltrative lung disease: comparison of diagnostic accuracies of radiography and low- and conventional-dose thin-section CT Radiology 1994;191:669-673.
58. Kazerooni EF, Martinez F, Flint D, et al. Thin-section CT obtained at 10 mm increments versus three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. AJR Am J Roentgenol 1997;169:977-983.
59. Webb RW, Muller NL, Naidich DP. Clinical utility of high-resolution computed tomography. In: Webb RW, Muller NL, Naidich DP editors. High-resolution CT of the lun. Philadelphia PA: Lippincott William & Wilkins; 2001. p. 569-597.
60. Wells AU, Hansell DM, Rubens MB, et al. The predictive value of appearances of thin-section computed tomography in fibrosing alveolitis. Am Respir Dis 1993;148:1076-1082.
61. Zerhouni EA, Naidich DP, Stitik FP. et al. Computed tomography of the pulmonary parenchyma: part 2. Interstitial disease. J Thorac Imaging 1985;1:54-64.
62. Hunninghake GW, Zimmerman MB, Schwarz DA, et al. Utility of a lung biopsy for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2001;164:193-196.
63. McDonald SL, Rubens MB, Hansell DM, et al. Nonspecific interstitial pneumonia and usual interstitial pneumonia: comparative appearances at and diagnostic accuracy of thin-section CT. Radiology 2001;221:600-605.
64. Daniil ZD, Giltchrist FC, Nicholson AG, et al. A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 1999;160:899-905.
65. Flaherty KR, Twaite EL, Kazerooni EA, et al. Radiological versus histological diagnosis in UIP and NSIP: survival implications. Thorax 2003;58:143-148.
66. Gay SE, Kazerooni EA, Toews GB, et al. Idiopathic pulmonary fibrosis: predicting response to therapy and survival. Am J Respir Crit Care Med 1998;157:1063-1072.
67. King TE Jr, Schwarz MI, Brown K, et al. Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. Am J Respir Crit Care Med 2001;164:1025-1032.
68. King TE Jr, Tooze JA, Schwarz MI, et al. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 2001;164:1171-1181.
69. Wells AU, Desai SR, Rubens MB, et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med 2003;167:962-969.
70. Mogulkoc N, Brutsche MH, Bishop PW, et al. Pulmonary function in idiopathic pulmonary fibrosis and referral for lung transplantation Am J Respir Crit Care Med 2001;164:103-108.
71. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and management. International Consensus Statement. Am J Respir Crit Care Med 2000;161:646-664.
72. Awadh N, Muller NL, Park CS, et al. Airway wall thickness in patients with near fatal asthma and control groups: assessment with high resolution tomographic scanning. Thorax 1998;53:248-253.
73. Meyer KC. Bronchoalveolar lavage as a diagnostic tool. Semin Respir Crit Care Med 2007;28:546-560.
74. 67Ga scanning, bronchoalveolar lavage, and serum angiotensin-converting enzyme essay. J Comput Assist Tomogr 1998;22:229-234.
75. 67Ga images in the noninvasive diagnosis of sarcoidosis. Chest 1993;103:403-409.
76. Alavi A, Palevsky HI. Gallium-67 citrate scanning in the assessment of disease activity in sarcoidosis. J Nuc Med 1992;33:751-755.
77. 67Ga scintigraphy as an indicator of response to and prognosis after corticosteroid treatment in idiopathic interstitial pneumonia. J Nucl Med 2005;46:1421-1426.
78. Lebthai R, Crestani B, Belmatoug N, et al. Somatostatin receptor scintigraphy and gallium scintigraphy in patients with sarcoidosis. J Nucl Med 2001;42:21-26.
79. Carbone R, Filiberti R, Grosso M, et al. Octreoscan perspectives in sarcoidosis and idiopathic interstitial pneumonia. Eur Rev for Med and Pharmacol Sci 2003;7:97-105.
80. Turner-Warwick M, McAllister W, Lawrence R, et al. Corticosteroid treatement in pulmonary sarcoidosis: do serial lavage lymphocyte counts, serum angiotensin converting enzyme measurements and gallium-67 scan help management? Thorax 1986;41:903-913.
81. Clarke D, Mitchell A W M, Dick R, et al. The radiology of sarcoidosis. Sarcoidosis 1994;11:90-99.
82. Kwekkeboom DJ, Krenning EP, Kho GS, et al. Somatostatin receptor imaging in patients with sarcoidosis. Eur J Nucl Med 1998;25:1284-1292.
83. Carbone RG, Musi M, Cantalupi DP, et al. Somatostain receptor versus gallium-67 scintigraphy in interstitial lung diseases. Chest 1999;119:315S.
84. McGoon M, Gutterman D, Steen V, et al. Screening early detection, and diagnosis of pulmonary arterial hypertension. ACCP evidence-based clinical practice guidelines. Chest 2004;126:14S-34S.
85. Mukerjee D, St George D, Knight C, et al. Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology 2004;43:461-466.
86. Burdt MA, Hoffman RW, Deutscher SL, et al. Long term outcome in mixed connective tissue disease: longitudinal clinical and serologic findings. Arthritis Rheum 1999;42:899-990.
87. McQuillan BM, Picard MP, Leavitt M, et al. Clinical correlates and reference intervals for pulmonary artery systolic pressure among echocardiographically normal subjects. Circulation 2001;104:2797.
88. Barst RJ, McGoon M, Torbicki A, et al. Diagnosis and differential assessment of pulmonary hypertension. J Am Coll Cardiol 2004;43:40S-47S.
89. Stephen B, Dalal P, Berger M, et al. Noninvasive estimation of pulmonary artery diastolic pressure in patients with tricuspid regurgitation by Doppler echocardiography. Chest 1999;116:73-77.
90. Baughman R, Lower EE, Engel P. Echocardiography to detect pulmonary hypertension in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2005;22:244-245.
91. Sulica R, Teirstein AS, Kakarda S, et al. Distinctive clinical, radiological, and functional characteristics of patients with sarcoidosis-related pulmonary hypertension. Chest 2005;128:1483-1489.
92. Arcasoy SM, Christie JD, Ferrari VA, et al. Echocardiography assessment of pulmonary hypertension in patients with advanced lung disease. Am Respir J Crit Care 2003;167:735-740.
93. Nadrous HF, Pellika PA, Krowka MJ, et al. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest 2005;128:2393-2399.
94. Bourbon A, Vionnet M, Leprince P, et al. The effect of methylprednisolone treatment on the cardiopulmonary bypass-induced systemic inflammatory response. Eur Cardiothorac Surg 2005;27:729-730.
95. Gothard J. Lung injury after thoracic surgery and one-lung ventilation. Curr Opin Anaesthesiol 2006;19:5-10.
96. Ng CS, Wang S, Arifi AA, et al. Inflammatory response to pulmonary ischemia-reperfusion injury. Surg Today 2006;36:205-214.
97. Berg JT, Fu Z, Breen EC, et al. High lung inflation increases mRNA levels of ECM components and grown factors in lung parenchyma. J Appl Physiol 1997;83;120-128.
98. Berg JT, Breen EC, Fu Z, et al. Alveolar hypoxia increases gene expression of extra cellular matrix protein and platelet-derived growth factor-B in lung parenchyma. Am Respir Crit Care Med 1998;138:1920-1928.
99. Carbone R, Bossone E, Bottino G, et al. Secondary pulmonary hypertension-diagnosis and management. Eur Rev for Med Pharmacol Sci 2005;9:331-342.
100. Carbone R, Montanaro F, Bottino G. Outcome in interstitial lung disease. Eur Respir J 2005;26:268S.
101. Garbin U, Fratta Pasini A, Stranieri C, et al. Effects of nebivolol on endothelial gene expression during oxidative stress in human umbilical vein endothelial cells. Mediators Inflamm. 2008;2008:367590.
102. Lee SH, Channick RN, Endothelin antogonism in pulmonary arterial hypertension. Semin Respir Crit Care Med. 2005 Aug; 26(4):402-8. Review.
103. Ishaque A, Dunn MJ, Sorokin A, Cyclooxygenase-2 inhibits tumor necrosis factor alphamediated apoptosis in renal glomerular mesangial cells. J Biol Chem. 2003 Mar. 21;278(12):10629-40.